Events & Conferences

13 Oct 21 – KCSA Virtual Investor Conference

10:00 A.M. ET

Presentation: Small Pharma’s progress in the development of N,N-dimethyltryptamine (“DMT”) assisted therapy for the treatment of Major Depressive Disorder 

Presented by Peter Rands, CEO

 

Investor sign up: Registration link

For more information about the conference, or to schedule a one-on-one meeting with Small Pharma’s management team, please contact KCSA Strategic Communications at SmallPharmaIR@kcsa.com.

About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

Get Small Pharma
Investor Updates

    Investor Deck

    Follow us: